Regeneron Wins FDA Approval for First siRNA Therapy in gMG

Share on Social Media

FDA approves Regeneron's Livsayis (cemdisiran), the first siRNA therapy for generalized myasthenia gravis with once-quarterly subcutaneous dosing.

FDA approves Regeneron’s Livsayis (cemdisiran), the first siRNA therapy for anti-AChR-positive generalized myasthenia gravis, with once-quarterly dosing.

Written By: Kirti Kumbhar, M. Pharm (QA)

Reviewed By: Pharmacally Editorial Team

Regeneron Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has approved Livsayis™ (cemdisiran) for the treatment of adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG). The approval introduces the first small interfering RNA (siRNA) therapy for gMG and the only FDA-approved treatment for the condition administered subcutaneously four times a year (once every three months).

Cemdisiran is a complement component 5 (C5)-directed siRNA therapeutic designed to reduce circulating C5 protein by degrading the messenger RNA (mRNA) responsible for its hepatic production. By silencing C5 synthesis upstream, the therapy limits terminal complement activation, which drives complement-mediated damage at the neuromuscular junction in anti-AChR antibody-positive gMG. This milestone marks Regeneron’s first approved siRNA therapy as well as its first approved medicine in neurology.

Phase 3 NIMBLE Trial: Study Design and Population

The FDA approval is supported by results from NIMBLE (NCT05070858), an ongoing, randomized, double-blind, placebo-controlled Phase 3 trial conducted across 86 centers in 13 countries, with 284 adult participants randomized.

While the trial enrolled adults with gMG who tested positive for either anti-AChR or anti-low-density lipoprotein receptor-related protein 4 (LRP4) antibodies, the FDA-approved indication for Livsayis is narrower and covers only adults with anti-AChR antibody-positive gMG. The broader clinical trial eligibility should therefore not be interpreted as regulatory approval for the anti-LRP4-positive population.

Participants were randomized to one of four subcutaneous treatment regimens:

  • Cemdisiran monotherapy: 600 mg every 12 weeks (the FDA-approved regimen)
  • Combination therapy: Cemdisiran (200 mg) combined with the C5-inhibiting monoclonal antibody pozelimab (200 mg) every four weeks
  • Pozelimab monotherapy: 200 mg every four weeks
  • Placebo: Administered every four weeks

Stable background immunosuppressant therapy was permitted to continue throughout the trial at the investigator’s discretion. The primary endpoint was the change from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score at Week 24, and the key secondary endpoint was the change from baseline in the Quantitative Myasthenia Gravis (QMG) score at Week 24. Efficacy outcomes reported below reflect the FDA-approved cemdisiran monotherapy regimen versus placebo.

Clinical Efficacy Results

Primary Endpoint: MG-ADL at Week 24

Cemdisiran monotherapy demonstrated a statistically significant improvement in MG-ADL total score compared with placebo at Week 24:

  • Cemdisiran: 4.5-point least-squares mean improvement (SE 0.4)
  • Placebo: 2.2-point least-squares mean improvement (SE 0.5)
  • Placebo-adjusted difference: 2.3 points (P=O.OOO5)

Additionally, 76.6% of participants receiving cemdisiran achieved a clinically meaningful improvement of at least 3 points on the MG-ADL scale at Week 24, compared with 44.1% of participants receiving placebo ( less than ).

Key Secondary Endpoint: QMG at Week 24

Improvements in muscle strength and fatigability, as measured by the QMG score, also favored cemdisiran over placebo:

  • Cemdisiran: 4.2-point least-squares mean improvement (SE 0.6)
  • Placebo: 1.5-point least-squares mean improvement (SE 0.7)
  • Placebo-adjusted difference: 2.8 points based on unrounded figures (P=O.OO15)

A QMG response defined as an improvement of at least 5 points from baseline was achieved by 48.4% of cemdisiran-treated participants compared with 19.0% of those receiving placebo (less than).

Onset and Durability of Response

Regeneron reported clinically meaningful MG-ADL improvements of 2.5 points as early as two weeks following treatment initiation, with clinical benefits deepening over time. Disease control was sustained throughout the 24-week assessment period without evidence of waning efficacy between quarterly doses.

Safety and Infection-Related Precautions

Consistent with the mechanism of terminal complement inhibition, the prescribing information for Livsayis carries a Boxed Warning for serious and life-threatening meningococcal infections. The most common adverse reactions occurring in at least 5% of cemdisiran-treated patients and more frequently than with placebo—were injection-site reactions, viral infections, and urinary tract infections.

Because of the risk of meningococcal disease, Livsayis is subject to strict safety requirements:

  • REMS Program: Livsayis is available only through a restricted distribution program under the Livsayis Risk Evaluation and Mitigation Strategy (REMS).
  • Vaccination Requirements: Patients must complete or update meningococcal vaccination (covering serogroups A, C, W, Y, and B in accordance with current ACIP recommendations) at least two weeks prior to receiving their first dose.
  • Urgent Initiation Protocol: If urgent therapy is required in an unvaccinated patient, required vaccines must be administered as soon as possible, and the patient must receive concomitant antibacterial drug prophylaxis for at least two weeks after vaccination.
  • Ongoing Monitoring: Because vaccination reduces but does not eliminate infection risk, patients must be monitored closely for early signs of meningococcal infection and must carry a Patient Safety Card throughout treatment and for 12 months after their final dose.

Livsayis is contraindicated in patients with unresolved serious Neisseria meningitidis infection. Safety and effectiveness in pediatric patients have not been established.

Regulatory Outlook and Development Responsibilities

Regeneron holds sole responsibility for the global development, manufacturing and commercialization of cemdisiran under a worldwide licensing agreement with Alnylam Pharmaceuticals. In June 2026, the FDA accepted Regeneron’s New Drug Application (NDA) for cemdisiran under Priority Review, following the company’s use of a Priority Review Voucher. The application had a target FDA action date of November 2026, ahead of its approval on November 18, 2026.

Beyond the U.S. approval, a marketing authorization application for gMG is currently under review in the European Union, with a European Commission decision anticipated in the second half of 2027. Additional regulatory submissions are planned in international markets, including Japan.

Clinical Interpretation

The approval of Livsayis introduces a distinct RNA interference-based modality to the complement inhibitor class for anti-AChR antibody-positive gMG. In the Phase 3 NIMBLE trial, quarterly subcutaneous administration delivered rapid and sustained improvements across both patient-reported daily functioning (MG-ADL) and clinician-assessed muscle strength (QMG), supported by substantially higher responder rates than placebo.

Its once-every-three-months subcutaneous dosing schedule offers a meaningful convenience advantage over existing complement inhibitors, which typically require intravenous infusions or more frequent subcutaneous injections. In clinical practice, however, clinicians will need to weigh this extended dosing interval against the serious infection risks inherent to C5 suppression, mandatory meningococcal vaccination timelines, and REMS enrollment requirements. Longer-term extension data from NIMBLE and real-world experience will further define its role in the longitudinal management of gMG.

Reference

Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing, Regeneron, 18 November 2026

Tuan Vu et al, Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial, The Lancet, Volume 407, Issue 10540, 2026, Pages 1712-1725, https://doi.org/10.1016/S0140-6736(26)00690-2

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients with Generalized Myasthenia Gravis (NIMBLE), ClinicalTrials.gov ID NCT05070858

About the Writer

Kirti Kumbhar (LinkedIn) is an M.Pharm graduate with experience in Quality Assurance at Lupin Limited and a strong interest in clinical research, regulatory affairs, and Trial Master File (TMF) management. She has developed knowledge of regulatory documentation, quality systems, compliance, and healthcare research through her professional experience. Passionate about clinical development and continuous learning, Kirti is committed to supporting high-quality healthcare documentation, regulatory excellence, and research-driven healthcare advancements.


Share on Social Media
Scroll to Top